Hereditary Breast and Ovarian Cancer Syndrome
"Hereditary Breast and Ovarian Cancer Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Autosomal dominant HEREDITARY CANCER SYNDROME in which a mutation most often in either BRCA1 or BRCA2 is associated with a significantly increased risk for breast and ovarian cancers.
| Descriptor ID |
D061325
|
| MeSH Number(s) |
C04.588.180.483 C04.588.322.455.431 C04.700.517 C13.351.500.056.630.705.431 C13.351.937.418.685.431 C16.320.700.517 C17.800.090.500.483 C19.344.410.431 C19.391.630.705.431
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hereditary Breast and Ovarian Cancer Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Hereditary Breast and Ovarian Cancer Syndrome".
This graph shows the total number of publications written about "Hereditary Breast and Ovarian Cancer Syndrome" by people in this website by year, and whether "Hereditary Breast and Ovarian Cancer Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2021 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hereditary Breast and Ovarian Cancer Syndrome" by people in Profiles.
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors. J Genet Couns. 2021 04; 30(2):342-360.
-
Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clin Genet. 2019 02; 95(2):293-301.
-
Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules. Am J Obstet Gynecol. 2017 12; 217(6):652-660.
-
Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat. 2012 Jul; 134(2):889-94.
-
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res. 2012 Feb 20; 14(1):R33.